Cencora, Inc. $COR Shares Purchased by Chase Investment Counsel Corp

Chase Investment Counsel Corp boosted its stake in Cencora, Inc. (NYSE:COR) by 457.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,015 shares of the company’s stock after purchasing an additional 9,861 shares during the period. Chase Investment Counsel Corp’s holdings in Cencora were worth $4,058,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in COR. United Bank increased its holdings in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after purchasing an additional 305 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in Cencora in the 2nd quarter valued at $595,000. Treasurer of the State of North Carolina increased its holdings in Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC increased its holdings in Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after purchasing an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after purchasing an additional 15,154 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of COR stock opened at $256.96 on Monday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company’s 50-day simple moving average is $314.65 and its 200-day simple moving average is $339.24. The stock has a market capitalization of $49.99 billion, a price-to-earnings ratio of 19.71, a PEG ratio of 1.19 and a beta of 0.64.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the business posted $4.42 EPS. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. William Blair initiated coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a research note on Monday, May 4th. Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Finally, Robert W. Baird lowered their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.